Diagnostic power of the mid-regional pro-atrial natriuretic peptide for heart failure patients with dyspnea: a meta-analysis

Z Hu, Z Han, Y Huang, Y Sun, B Li, A Deng - Clinical biochemistry, 2012 - Elsevier
Z Hu, Z Han, Y Huang, Y Sun, B Li, A Deng
Clinical biochemistry, 2012•Elsevier
OBJECTIVE: To evaluate the diagnostic performance of the mid-regional portion of the pro-
atrial natriuretic peptide (MR-proANP) for heart failure (HF) in dyspnea patients. DESIGN
AND METHODS: We performed a systematic review of English-language studies published
during the past three decades. The performance characteristics (diagnostic sensitivity,
specificity, and other measures of accuracy) were pooled and examined by random-effects
models. RESULTS: Five studies met the inclusion criteria, which included 1153 patients with …
OBJECTIVE
To evaluate the diagnostic performance of the mid-regional portion of the pro-atrial natriuretic peptide (MR-proANP) for heart failure (HF) in dyspnea patients.
DESIGN AND METHODS
We performed a systematic review of English-language studies published during the past three decades. The performance characteristics (diagnostic sensitivity, specificity, and other measures of accuracy) were pooled and examined by random-effects models.
RESULTS
Five studies met the inclusion criteria, which included 1153 patients with HF and 1904 non-HF patients. The summary estimates for MR-proANP in HF diagnosis had a diagnostic sensitivity of 0.90 (95% confidence interval (CI), 0.88–0.92), a specificity of 0.68 (95% CI, 0.66–0.70), and a diagnostic odds ratio (DOR) of 22.89 (95% CI, 12.54–41.77). The area under the curve (AUC) and Q value for the summary receiver operating characteristic (sROC) curves were 0.88 and 0.81, respectively.
CONCLUSION
MR-proANP showed a high diagnostic accuracy for HF in dyspnea patients.
Elsevier
展开收起
被引用次数：24 相关文章 所有 6 个版本
以上显示的是最相近的搜索结果。 查看全部搜索结果